Westmount Partners LLC Buys 279 Shares of Novo Nordisk A/S (NYSE:NVO)

Westmount Partners LLC grew its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 13.1% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,405 shares of the company’s stock after acquiring an additional 279 shares during the period. Westmount Partners LLC’s holdings in Novo Nordisk A/S were worth $207,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of NVO. Meeder Advisory Services Inc. bought a new stake in shares of Novo Nordisk A/S during the second quarter valued at approximately $884,000. GHP Investment Advisors Inc. increased its holdings in Novo Nordisk A/S by 2.9% during the second quarter. GHP Investment Advisors Inc. now owns 4,694 shares of the company’s stock valued at $670,000 after buying an additional 134 shares during the period. J.W. Cole Advisors Inc. increased its holdings in Novo Nordisk A/S by 57.7% during the second quarter. J.W. Cole Advisors Inc. now owns 14,553 shares of the company’s stock valued at $2,077,000 after buying an additional 5,322 shares during the period. Diversify Wealth Management LLC purchased a new position in Novo Nordisk A/S during the second quarter valued at approximately $4,940,000. Finally, Pinion Investment Advisors LLC purchased a new position in Novo Nordisk A/S during the second quarter valued at approximately $353,000. Institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on NVO. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, BMO Capital Markets dropped their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock traded down $1.90 during trading hours on Monday, reaching $84.36. The stock had a trading volume of 5,034,926 shares, compared to its average volume of 7,056,390. The stock’s 50 day moving average is $100.35 and its 200 day moving average is $119.04. The firm has a market capitalization of $378.57 billion, a PE ratio of 27.30, a PEG ratio of 1.37 and a beta of 0.45. Novo Nordisk A/S has a twelve month low of $81.50 and a twelve month high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.